Continuation of trading halt
Filed with ASX · · 1 page · English
Summary by 6ix AI
Syntara Limited has requested a continuation of its trading halt pending an announcement regarding a proposed capital raising related to correspondence from the U.S. Food and Drug Administration. The trading halt will remain in effect until the earlier of the commencement of trading on a specified date or the announcement of the capital raising.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Syntara
- Positive FDA feedback for Amsulostat P2b trial
- Half Year Report and Appendix 4D
- Quarterly Activities/Appendix 4C Cash Flow Report
- Amsulostat and Garvan in MRFF funded pancreatic trial
- SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited
Later from Syntara
- $8m placement and share purchase plan
- Share Purchase Plan Offer Booklet
- Results of Share Purchase Plan
- Encouraging SNT-4728 Phase 2 iRBD results
- Appendix 4E and Annual Report
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara